Brief: Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
04/06/2026 22:11
BRIEF-Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium June 4 (Reuters) - Cloudbreak Pharma Inc 2592.HK:
CLOUDBREAK PHARMA ANNOUNCES FINAL PATIENT VISIT FOR 12-MONTH EFFICACY ENDPOINT IN PHASE 3 STUDY OF CBT-001 AS A POTENTIAL TREATMENT FOR PTERYGIUM
CLOUDBREAK PHARMA - TOPLINE 12-MONTH EFFICACY DATA FOR CBT-1 PHASE 3 TRIAL EXPECTED IN Q3 2026
Source text: ID:nGNX1BvWLf
Further company coverage: 2592.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cloudbreak Pharma
See all newsHong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Hong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Brief: Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection
Brief: Cloudbreak Pharma Enters Share Subscription Agreement With Arc Group International For Up To $15 Mln
Brief: Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium